CHATSWORTH, Calif., May 26, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that Chairman, President and Chief Executive Officer, César M. García,will present an overview of the Company at the Jefferies 2011 Global Healthcare Conference, June 6-9, 2011 at the Grand Hyatt Hotel in New York City. Mr. García is scheduled to present on Thursday, June 9 at 10:30 a.m. Eastern Time. In addition, Mr. García, along with CFO Amin Khalifa and CTO Dr. Thomas Adams, will be available for one-on-one meetings with institutional investors at the conference throughout the day on June 9.
For those who are unable to attend, a live audio web cast may be accessed via the Investor's section of the IRIS website at http://www.proiris.com, or at Jefferies Global Healthcare Webcast. A replay will be archived on the Company's website for 90 days.
The Jefferies 2011 Global Healthcare Conference will feature informative presentations from more than 300 leading public and private healthcare companies across the healthcare services, life sciences, medical technology, healthcare IT, and biopharmaceuticals sectors. For additional information, please contact your Jefferies sales representative, or visit http://www.jefferies.com.
About IRIS International, Inc.
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 3,000 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets, and is developing applications in hematology and body fluids. In addition, the Company recently acquired a high complexity CLIA-certified molecular pathology laboratory offering differentiated, high value molecular diagnostic services in the rapidly growing field of personalized medicine. The laboratory provides a direct commercial channel for the Company's NADiA® ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com.